Rigel Pharmaceuticals (RIGL)
(Delayed Data from NSDQ)
$21.91 USD
+0.85 (4.04%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $21.88 -0.03 (-0.14%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
RIGL 21.91 +0.85(4.04%)
Will RIGL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RIGL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RIGL
Collegium Pharmaceutical (COLL) Q2 Earnings Preview: What's in the Cards?
Why Rigel (RIGL) Could Beat Earnings Estimates Again
RIGL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Rigel (RIGL) Climb 69.55% to Reach the Level Wall Street Analysts Expect?
Are Investors Undervaluing Rigel Pharmaceuticals (RIGL) Right Now?
Is Rigel Pharmaceuticals (RIGL) Stock Undervalued Right Now?
Other News for RIGL
Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and ...
RIGL Crosses Above Key Moving Average Level
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | ...
RIGL Makes Bullish Cross Above Critical Moving Average
Nuvation Bio: Judgement Day Grows Closer